As of 2025-05-24, the Intrinsic Value of Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766.SZ) is 2.59 CNY. This 000766.SZ valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 19.87 CNY, the upside of Tonghua Golden-Horse Pharmaceutical Industry Co Ltd is -87.00%.
The range of the Intrinsic Value is 1.31 - 6.31 CNY
Based on its market price of 19.87 CNY and our intrinsic valuation, Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766.SZ) is overvalued by 87.00%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 1.31 - 6.31 | 2.59 | -87.0% |
| DCF (Growth 10y) | 1.38 - 5.82 | 2.52 | -87.3% |
| DCF (EBITDA 5y) | 1.87 - 5.65 | 3.67 | -81.5% |
| DCF (EBITDA 10y) | 1.94 - 5.62 | 3.62 | -81.8% |
| Fair Value | 1.52 - 1.52 | 1.52 | -92.34% |
| P/E | 1.08 - 1.66 | 1.28 | -93.5% |
| EV/EBITDA | 0.70 - 3.71 | 1.59 | -92.0% |
| EPV | (0.23) - 0.18 | (0.03) | -100.1% |
| DDM - Stable | 0.63 - 2.27 | 1.45 | -92.7% |
| DDM - Multi | 1.44 - 3.51 | 1.99 | -90.0% |
| Market Cap (mil) | 19,204.16 |
| Beta | 1.20 |
| Outstanding shares (mil) | 966.49 |
| Enterprise Value (mil) | 20,799.01 |
| Market risk premium | 6.13% |
| Cost of Equity | 8.56% |
| Cost of Debt | 5.00% |
| WACC | 8.14% |